• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mangalore, Aug. 25 The Canada-based Apotex Pharmachem Inc, which has operations at Bangalore, is planning to make the unit as the largest R&D (research and development) centre outside Canada.

In this regard, it is planning to recruit nearly 150 people in the next six months, in addition to around 100 people already working there.

In an informal chat with Business Line on the sidelines of Prof B.S. Holla Endowment Lecture at Mangalore University here on Saturday, Dr K.S. Keshava Murthy, President of Apotex Pharmachem Inc, Canada, said that Apotex Pharmachem I ndia Pvt Ltd would have 250 people in the next six months. The company undertakes R&D activities focused mainly on process verification and development of APIs (active pharmaceutical ingredients).

The technology developed here can be transferred to other Indian contract manufacturing sites for the manufacture of select APIs.

Earlier delivering the endowment lecture on the topic ‘From molecule to market: A chemist’s journey in global pharmaceutical business’, Dr Murthy said global growth of pharma industry opens up opportunities for science and engineering graduates in a big way. Global pharmaceutical business is estimated at $550 billion, and India and China will become the prominent markets for the industry in the coming years, he said.

More Stories on : Outlook | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ITC e-Choupal to focus on product traceability

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line